Logo image of MED

MEDIFAST INC (MED) Stock Fundamental Analysis

NYSE:MED - New York Stock Exchange, Inc. - US58470H1014 - Common Stock - Currency: USD

14.05  +0.48 (+3.54%)

After market: 14.05 0 (0%)

Fundamental Rating

5

Overall MED gets a fundamental rating of 5 out of 10. We evaluated MED against 35 industry peers in the Personal Care Products industry. MED is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MED has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
In the past 5 years MED has always been profitable.
In the past 5 years MED always reported a positive cash flow from operatings.
MED Yearly Net Income VS EBIT VS OCF VS FCFMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of -2.50%, MED perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
The Return On Equity of MED (-3.32%) is comparable to the rest of the industry.
MED's Return On Invested Capital of 3.65% is in line compared to the rest of the industry. MED outperforms 51.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MED is significantly above the industry average of 15.14%.
The last Return On Invested Capital (3.65%) for MED is well below the 3 year average (38.03%), which needs to be investigated, but indicates that MED had better years and this may not be a problem.
Industry RankSector Rank
ROA -2.5%
ROE -3.32%
ROIC 3.65%
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
MED Yearly ROA, ROE, ROICMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

In the last couple of years the Profit Margin of MED has declined.
MED's Operating Margin of 2.23% is in line compared to the rest of the industry. MED outperforms 45.71% of its industry peers.
MED's Operating Margin has declined in the last couple of years.
MED's Gross Margin of 73.89% is amongst the best of the industry. MED outperforms 82.86% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 2.23%
PM (TTM) N/A
GM 73.89%
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
MED Yearly Profit, Operating, Gross MarginsMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MED is creating value.
The number of shares outstanding for MED has been increased compared to 1 year ago.
MED has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MED Yearly Shares OutstandingMED Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MED Yearly Total Debt VS Total AssetsMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 4.91 indicates that MED is not in any danger for bankruptcy at the moment.
MED has a better Altman-Z score (4.91) than 77.14% of its industry peers.
MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.91
ROIC/WACC0.41
WACC8.93%
MED Yearly LT Debt VS Equity VS FCFMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

MED has a Current Ratio of 3.52. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
MED has a Current ratio of 3.52. This is amongst the best in the industry. MED outperforms 85.71% of its industry peers.
MED has a Quick Ratio of 2.87. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
MED's Quick ratio of 2.87 is amongst the best of the industry. MED outperforms 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 2.87
MED Yearly Current Assets VS Current LiabilitesMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

0

3. Growth

3.1 Past

The earnings per share for MED have decreased strongly by -79.59% in the last year.
Measured over the past years, MED shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.59% on average per year.
The Revenue for MED has decreased by -39.47% in the past year. This is quite bad
Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.
EPS 1Y (TTM)-79.59%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-118.94%
Revenue 1Y (TTM)-39.47%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-33.77%

3.2 Future

Based on estimates for the next years, MED will show a very negative growth in Earnings Per Share. The EPS will decrease by -62.84% on average per year.
Based on estimates for the next years, MED will show a very negative growth in Revenue. The Revenue will decrease by -20.71% on average per year.
EPS Next Y-149.75%
EPS Next 2Y-62.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-34.73%
Revenue Next 2Y-20.71%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MED Yearly Revenue VS EstimatesMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
MED Yearly EPS VS EstimatesMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 10

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.24, the valuation of MED can be described as very reasonable.
Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.15, MED is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 11.24
Fwd PE N/A
MED Price Earnings VS Forward Price EarningsMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, MED is valued cheaply inside the industry as 88.57% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.47
EV/EBITDA -3.56
MED Per share dataMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

MED has a very decent profitability rating, which may justify a higher PE ratio.
MED's earnings are expected to decrease with -62.84% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.84%
EPS Next 3YN/A

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 9.97%, MED is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 5.83, MED pays a better dividend. On top of this MED pays more dividend than 97.14% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, MED pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.97%

5.2 History

The dividend of MED decreases each year by -53.42%.
MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
MED Yearly Dividends per shareMED Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

5.3 Sustainability

MED has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP-2.84%
EPS Next 2Y-62.84%
EPS Next 3YN/A
MED Yearly Income VS Free CF VS DividendMED Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

MEDIFAST INC

NYSE:MED (6/30/2025, 6:40:00 PM)

After market: 14.05 0 (0%)

14.05

+0.48 (+3.54%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners76.42%
Inst Owner Change-6.5%
Ins Owners2.71%
Ins Owner Change17.98%
Market Cap154.41M
Analysts45
Price Target15.3 (8.9%)
Short Float %12.45%
Short Ratio5.8
Dividend
Industry RankSector Rank
Dividend Yield 9.97%
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP-2.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)108.02%
Min EPS beat(2)54.16%
Max EPS beat(2)161.88%
EPS beat(4)4
Avg EPS beat(4)143.68%
Min EPS beat(4)54.16%
Max EPS beat(4)225.1%
EPS beat(8)6
Avg EPS beat(8)87.84%
EPS beat(12)10
Avg EPS beat(12)72.86%
EPS beat(16)13
Avg EPS beat(16)57.2%
Revenue beat(2)2
Avg Revenue beat(2)3.6%
Min Revenue beat(2)3.13%
Max Revenue beat(2)4.07%
Revenue beat(4)3
Avg Revenue beat(4)1.63%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)4.07%
Revenue beat(8)7
Avg Revenue beat(8)2.6%
Revenue beat(12)11
Avg Revenue beat(12)3.41%
Revenue beat(16)14
Avg Revenue beat(16)3.31%
PT rev (1m)0%
PT rev (3m)-4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-340%
EPS NY rev (1m)0%
EPS NY rev (3m)-132.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.81%
Valuation
Industry RankSector Rank
PE 11.24
Fwd PE N/A
P/S 0.28
P/FCF 11.47
P/OCF 7.5
P/B 0.73
P/tB 0.73
EV/EBITDA -3.56
EPS(TTM)1.25
EY8.9%
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)1.23
FCFY8.72%
OCF(TTM)1.87
OCFY13.34%
SpS49.45
BVpS19.2
TBVpS19.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.5%
ROE -3.32%
ROCE 5.52%
ROIC 3.65%
ROICexc 14.62%
ROICexgc 14.62%
OM 2.23%
PM (TTM) N/A
GM 73.89%
FCFM 2.48%
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
ROICexc(3y)95.28%
ROICexc(5y)N/A
ROICexgc(3y)95.28%
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexcg growth 3Y-42.96%
ROICexcg growth 5Y-39.1%
ROICexc growth 3Y-42.96%
ROICexc growth 5Y-39.1%
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.94
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 56.07%
Cap/Sales 1.31%
Interest Coverage 250
Cash Conversion 82.96%
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 2.87
Altman-Z 4.91
F-Score5
WACC8.93%
ROIC/WACC0.41
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-79.59%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-118.94%
EPS Next Y-149.75%
EPS Next 2Y-62.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.47%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-33.77%
Revenue Next Year-34.73%
Revenue Next 2Y-20.71%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-85.02%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-125.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-93.24%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-90.42%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%